Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04242342
Active, not recruiting Not applicable

Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors

NCT04242342 · tracked via the Priya Life Science France tracker
Sponsor
Centre Georges Francois Leclerc
Phase
Not applicable
Started
2020-01-20
Last updated
2024-02-12

Condition(s) studied

Radiotherapy

Investigational drug(s) / intervention(s)

Adaptative MR-Guided Stereotactic Body Radiotherapy

Adaptative MR-Guided Stereotactic Body Radiotherapy: If lesion near organs at risk: * Prescription of 50 Gy in 5 fractions of 10 Gy * 3 sessions per week, with MRI guided stereotactic radiotherapy and daily adaptive treatment If lesion far of organs at risk: * Prescription of 60 Gy in 6 fractions of 10 Gy * 3 sessions per week, with MRI guided stereotactic radiotherapy without daily adaptive treatment

Study summary

Hepatic metastases are common in solid cancers (up to 30% of patients with colorectal cancer and up to 50% of patients during their follow-up). The incidence of primary liver cancer increases due to the increase in chronic liver diseases induced by excessive alcohol consumption, hepatitis B and C viruses, and excess fat in the liver. Surgical excision of these liver lesions is the reference treatment but it cannot always be realised.

Stereotactic radiotherapy is a recent technique proposed to hepatic metastases treatment from solid cancers and primary hepatic lesions (HCC or cholangiocarcinomas); it is possible to deliver high doses of radiation in the most conformational way possible in order to limit the irradiation of the non-tumor liver. The results of this stereotactic radiotherapy are currently very good with control rates of 75 to 80% at 1 and 2 years with acceptable rates of severe toxicities of 10%. However, the fear of hepatic, digestive (colon, esophagus, stomach) or even cardiac toxicities limits its using to the majority of patients because coupled with a conventional scanner it do not allow direct visualization of the lesion.

Due to its non-irradiating nature, MRI guided stereotactic radiotherapy can generate continuous imaging, during the irradiation session, offering " in live " a visualization of the tumor target and organs at risk of proximity. In increasing the precision and safety in the delivery of irradiation, it allows to hope for several areas for improvement of treatment:

* reduced uncertainty margins
* an increase in the dose delivered
* the accessibility of tumor lesions near sensitive organs (esophagus, stomach, heart chambers, intestines, duodenum, right kidney).

More, this accelerator allows a re-optimization of the initial dosimetric plan to the anatomical changes of the day to allow an MRI guided adaptive radiotherapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Man or woman aged 18 or over. 2. Performance Status 0 or 1. 3. Primary or secondary liver tumor(s) 4. maximum 1 to 3 liver tumor(s) accessible to stereotaxic body radiotherapy therapy. 5. ASAT and ALAT \<3 times the upper limit of normal, 6. Albuminemia ≥ 28g / L. 7. Creatinine clearance\> 30ml / min 8. signing of informed consent. 9. Woman of childbearing age who accepts effective contraception during the course of treatment and within 3 months of treatment. 10. Patient affiliated to a social security scheme. Exclusion Criteria: 1. MRI contraindication 2. Pregnant or breastfeeding woman. 3. Patient with decompensated liver cirrhosis or cirrhosis\> Child B7 4. Patient previously irradiated in the planned treatment area. 5. Refusal of patient's consent. 6. Patient unable to give his consent, under guardianship or unable to submit to the treatment protocol or protocol follow-up. 7. History of another malignant tumor except: * Malignant neoplasm treated with curative intent and with no known active disease ≥ 5 years before inclusion, * Non-melanoma or malignant lentigo skin cancer treated adequately without signs of disease, * Carcinoma in situ treated without sign of disease, * Prostate carcinoma that did not require curative treatment. 8. Known hypersensitivity to gadolinium or other gadolinium chelates. 9. Patient participating in another therapeutic trial which would require the administration of experimental treatment during the period between inclusion and the end of radiotherapy treatment.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Centre Georges François Leclerc Dijon France

More Centre Georges Francois Leclerc trials in France

Impact of Non-magnetic Screen Respiratory Self-guidance During MRI-guided Radiotherapy Sessions for Mobile Lesions Recruiting
Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine Recruiting
FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM) Recruiting
Functional Evaluation After Breast Reconstruction With a Minimally Invasive Latissimus Dorsi Flap Following Radical Surgery for Breast Cancer. Active, not recruiting
Influence of Food Preferences on the Occurrence of Undernutrition in Treated Patients for Bronchopulmonary Carcinoma Non-small Cell Stage IV Active, not recruiting

Other trials for the same condition

Hippotherapy Teenager-pediatric Radiotherapy Recruiting
Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort Recruiting
Interest of a Weekly Consultation by a Medical Electro Radiology Manipulator (MERM) in Addition to the Follow-up by the Radiotherapist to Improve the Collection of Radio-induced Toxicities in Patients Undergoing Proton Therapy Active, not recruiting
Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy Recruiting
A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04242342 on ClinicalTrials.gov ↗ ← All trials in France